Can-Fite reports longer-than-expected survival in Phase III Namodenoson liver cancer trial

• Can-Fite flagged longer-than-anticipated overall survival in its ongoing pivotal Phase III Namodenoson trial in advanced liver cancer.
• Results have not been presented; the study remains blinded, so the observation does not indicate whether Namodenoson outperformed placebo.
• The signal reflects the pooled study population, suggesting patients are living longer than expected under the trial’s original assumptions.
• Management is evaluating moving up the planned interim analysis to compare survival between treatment groups under the statistical plan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609020700PRIMZONEFULLFEED9820190) on September 02, 2026, and is solely responsible for the information contained therein.